Spruce Street Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Spruce Street Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-897,681	Closed	-$18.1M	–	32
2026 Q1	$18.1M	Buy	897,681 +509,713	+131%	+$8.22M	4.34%	9
2025 Q4	$6.27M	Buy	+387,968	New	+$5.14M	2.07%	19

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Spruce Street Capital's KALV Position: Q2 2026 in Review

Spruce Street Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 897,681 shares — an estimated $18.1M sold.

Spruce Street Capital first reported a position in KALV in Q4 2025 and held it in 2 quarters. The position peaked at $18.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Spruce Street Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Spruce Street Capital sold 897,681 KalVista Pharmaceuticals shares in Q2 2026, an estimated $18.1M.
Spruce Street Capital first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Spruce Street Capital's KalVista Pharmaceuticals position peaked at $18.1M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.